Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) EPS (Weighted Average and Diluted) (2023 - 2025)

CG Oncology (CGON) has disclosed EPS (Weighted Average and Diluted) for 3 consecutive years, with -$0.51 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 6.25% year-over-year to -$0.51, compared with a TTM value of -$2.08 through Dec 2025, down 46.48%, and an annual FY2025 reading of -$2.08, down 47.52% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.51 for Q4 2025 at CG Oncology, up from -$0.58 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.28 in Q2 2024 and bottomed at -$4.5 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$1.6, with a median of -$0.52 recorded in 2025.
  • The sharpest move saw EPS (Weighted Average and Diluted) soared 92.88% in 2024, then crashed 93.33% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$4.5 in 2023, then skyrocketed by 89.33% to -$0.48 in 2024, then fell by 6.25% to -$0.51 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CGON at -$0.51 in Q4 2025, -$0.58 in Q3 2025, and -$0.54 in Q2 2025.